Valeant launches new chemotherapy management guide

27 August 2006

California, USA-based Valeant Pharmaceuticals says it will make "Managing Chemotherapy Side Effects for Dummies", its new complimentary resource, available to both patients and their caregivers. The book is part of the popular "For Dummies..." series and was written in a collaboration between a medical oncologist, a supportive care physician and a nurse, along with a professional writer who has survived cancer.

The launch coincides with Valeant's announcement of the availability of its Cesamet (nabilone) capsules for the treatment of nausea and vomiting associated with chemotherapy. The drug is a cannabinoid-based product designed for patients who have failed to respond to traditional anti-emetic treatments.

The book "Managing Chemotherapy Side Effects for Dummies" is available on-line at: www.chemofordummies.com.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight